Why Two-Thirds of Alzheimer’s Patients Are Women
It’s not because women live longer. Not really. Sure, longevity plays a part—but if that were the whole story, we’d see the same pattern in every neurodegenerative disease. We don’t. Parkinson’s? Roughly equal. ALS? Slightly more men. But Alzheimer’s? Nearly 65% women. And we’ve been chasing amyloid plaques like they’re the villain in a superhero movie (even as other research links poor sleep and genetic variants directly to accelerated brain shrinkage), while the real collapse—quiet, structural, invisible—has been happening in the spaces between neurons.
I’ve sat across from women in their 70s who’ve watched their mothers forget their own names. One told me, "I started HRT at 52. I don’t know if it’s helped, but I don’t want to end up like her." She didn’t ask for reassurance. She just wanted to know how to build resilience against Alzheimer's and understand why this is happening. She wanted someone to say: this isn’t random. It’s not bad luck. There’s a reason.
The reason is architecture.
The Hidden 20%: The Brain’s Structural Scaffold
We’ve spent decades staring at neurons. Synapses. Dendrites. Axons. We’ve mapped them like city streets, tracing every connection. But we’ve ignored the mortar.
The extracellular matrix—ECM—isn’t a passive filler. It’s not just glue. It’s a dynamic, living scaffold. It’s made of proteins, sugars, and signaling molecules that form a mesh around every neuron. Think of it like the steel rebar inside concrete. Without it, the structure doesn’t just weaken—it disintegrates.
And here’s the kicker: the ECM makes up nearly 20% of your brain’s volume. That’s not a footnote. That’s a cathedral.
In the hippocampus—the memory center—it’s especially dense. This isn’t decoration. It’s infrastructure. It holds neurons in place. Guides axons. Filters toxins. Regulates neurotransmitters. When the ECM degrades, synapses don’t just fire less—they lose their anchor. They drift. Disconnect. Die.
We didn’t know this because we weren’t looking. We were too busy hunting plaques.
Estrogen Isn’t Just a Hormone. It’s a Builder.
Estrogen doesn’t just regulate cycles. It doesn’t just influence mood. In the brain, it’s a structural architect.
Before menopause, ovaries crank it out. After? The brain tries to pick up the slack. Neurons and astrocytes start making their own—locally, in the hippocampus. It’s a backup system. A last-ditch effort.
But here’s what the Northwestern team discovered: in aging women, when estrogen drops—even a little—the ECM doesn’t just slow down its repair. It starts actively breaking down. Genes that build the matrix—Col1a1, Dcn, Ogn—go quiet. Enzymes that chew it up? They rev up.
And it’s sex-specific. Male mice? No change. Even when you knock out their aromatase, the enzyme that makes estrogen, their ECM stays intact. But in females? Collapse. Within months. Memory loss follows. It’s not correlation. It’s causation.
This isn’t about estrogen as a mood stabilizer. It’s about estrogen as a structural engineer. And when that engineer walks off the job, the building starts to fall.
The Northwestern Breakthrough: It’s Not the Cells. It’s the Space.
The study was elegant in its cruelty. They took mice—male and female, young and old—and deleted aromatase only in the brain. No ovaries. No systemic hormone swings. Just brain estrogen, gone.
What happened?
Only old female mice lost memory. Only they showed ECM degradation. Only their hippocampal gene expression lit up like a Christmas tree for matrix-disassembly pathways.
The researchers didn’t just find a correlation. They isolated the mechanism: estrogen loss → ECM collapse → memory failure. And it only happened in females. Not because they’re "weaker." But because their brains evolved to rely on this local estrogen supply after menopause. It’t not a flaw. It’s a design.
And now, that design is failing.
The paper’s authors, Dr. Hong Zhao and Dr. Serdar Bulun, put it bluntly: "Once memory is gone, it’s gone." They’re not being dramatic. They’re being accurate. The ECM isn’t like a protein you can clear away and rebuild. Once the scaffold is gone, the neurons don’t just get sick—they lose their home.
Why Lecanemab Fails
You’ve heard the headlines. Lecanemab. Donanemab. These drugs clear amyloid plaques. They’re expensive. They cause brain bleeds. And they barely slow decline.
Why?
Because they’re cleaning up the smoke while the house burns down.
Amyloid plaques? They’re a symptom. A byproduct. A kind of biological ash. But the foundation? The ECM? That’s the structural steel. And that’s what’s collapsing.
I’ve read the clinical trial data. The difference between placebo and lecanemab? A 22% slowing of decline over 18 months. That’s not a cure. That’s a delay. And it’s only in the earliest stages.
Meanwhile, the ECM keeps crumbling. No drug touches it. No scan sees it. We’re treating the fingerprint, not the burglar.
The Northwestern study doesn’t just explain why women are more vulnerable. It explains why our entire therapeutic paradigm is broken.
A New Horizon: Repairing the Scaffold
This isn’t about replacing estrogen like a broken battery. It’s about rebuilding the scaffold.
The future isn’t in broad-spectrum HRT. We’ve seen that fail—sometimes catastrophically. Too late. Too high. Wrong molecules.
The future is precision. Targeted delivery. Maybe a molecule that mimics estrogen’s effect on Col1a1 without triggering breast tissue growth. Maybe a gene therapy that reactivates the ECM’s repair genes—similar to how scientists are exploring targeted neuroprotective gene therapies to rescue dysfunctional brain cells. Maybe even a biologic scaffold you inject into the hippocampus—like a temporary steel frame while the brain rebuilds.
The women in the comments on that NeuroScience News article? They’re already trying. One wrote: "I’m on HRT for life. My mind feels like 30. No kidding."
She’s not wrong. But she’s also not the answer. She’s a symptom of what’s missing.
We need to stop asking: "How do we clear plaques?" and start asking: "How do we rebuild the space between neurons?"
Because memory isn’t stored in the cells.
It’s stored in the structure that holds them together.
And if we don’t fix that, nothing else will matter.